Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: An overview of their mechanisms of action

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue SUPPL.1, 2012, Pages

  Poupon, Raoul ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; NORURSODEOXYCHOLIC ACID; OBETICHOLIC ACID; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTATIC HEPATITIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LIVER CIRRHOSIS; LIVER FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; LIVER CIRRHOSIS, BILIARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84868698756     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(12)70015-3     Document Type: Article

References (117)

1. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
2. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
3. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999, 3:543-553.
4. Maruyama T., Miyamoto Y., Nakamura T., Tamai Y., Okada H., Sugiyama E., Nakamura T., et al. Identification of membranetype receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002, 298:714-719.
5. Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M., Fukusumi S., et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003, 278:9435-9440.
6. Hofmann A.F., Roda A. Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem. J Lipid Res 1984, 25:1477-1489.
7. Hofmann A.F., Mysels K.J. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res 1992, 33:617-626.
8. Holsti P. Experimental cirrhosis of the liver in rabbits induced by gastric instillation of desiccated whole bile. Acta Pathol Microbiol Scand Suppl 1956, 39:1-66.
9. Schmucker D.L., Ohta M., Kanai S., Sato Y., Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990, 12:1216-1221.
10. Becker S., Reinehr R., Graf D., vom Dahl S., Haussinger D. Hydrophobic bile salts induce hepatocyte shrinkage via NADPH oxidase activation. Cell Physiol Biochem 2007, 19:89-98.
11. Reinehr R., Becker S., Keitel V., Eberle A., Grether-Beck S., Haussinger D. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005, 129:2009-2031.
12. Allen K., Jaeschke H., Copple B.L. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011, 178:175-186.
13. Calmus Y., Arvieux C., Gane P., Boucher E., Nordlinger B., Rouger P., Poupon R. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 1992, 102:1371-1377.
14. Hillaire S., Boucher E., Calmus Y., Gane P., Ballet F., Franco D., Moukthar M., et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994, 107:781-788.
15. Arvieux C., Calmus Y., Gane P., Legendre C., Mariani P., Delelo R., Poupon R., et al. Immunogenicity of rat hepatocytes in vivo: effect of cholestasis-induced changes in major histocompatibility complex expression. J Hepatol 1993, 18:335-341.
16. Calmus Y., Guechot J., Podevin P., Bonnefis M.T., Giboudeau J., Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 1992, 16:719-723.
17. Podevin P., Calmus Y., Bonnefis M.T., Veyrunes C., Chereau C., Poupon R. Effect of cholestasis and bile acids on interferoninduced 2',5'-adenylate synthetase and NK cell activities. Gastroenterology 1995, 108:1192-1198.
18. Podevin P., Rosmorduc O., Conti F., Calmus Y., Meier P.J., Poupon R. Bile acids modulate the interferon signalling pathway. Hepatology 1999, 29:1840-1847.
19. Fiorucci S., Cipriani S., Mencarelli A., Renga B., Distrutti E., Baldelli F. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med 2010, 10:579-595.
20. Poupon R., Chretien Y., Poupon R.E., Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1987, 1:834-836.
21. Poupon R.E., Poupon R., Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994, 330:1342-1347.
22. Poupon R.E., Lindor K.D., Cauch-Dudek K., Dickson E.R., Poupon R., Heathcote E.J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-890.
23. Lindor K.D., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., Harnois D., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
24. Crosignani A., Setchell K.D., Invernizzi P., Larghi A., Rodrigues C.M., Podda M. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 1996, 30:333-358.
25. Bachrach W.H., Hofmann A.F. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II. Dig Dis Sci 1982, 27:833-856.
26. Lanzini A., De Tavonatti M.G., Panarotto B., Scalia S., Mora A., Benini F., Baisini O., et al. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration. Gut 2003, 52:1371-1375.
27. Chazouilleres O., Marteau P., Haniche M., Jian R., Poupon R. Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA). Dig Dis Sci 1996, 41:2417-2422.
28. Stiehl A. Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. Ital J Gastroenterol 1995, 27:193-195.
29. Jazrawi R.P., de Caestecker J.S., Goggin P.M., Britten A.J., Joseph A.E., Maxwell J.D., Northfield T.C. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994, 106:134-142.
30. Beuers U., Spengler U., Zwiebel F.M., Pauletzki J., Fischer S., Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992, 15:603-608.
31. Poupon R., Poupon R.E. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther 1995, 66:1-15.
32. Spirli C., Fabris L., Duner E., Fiorotto R., Ballardini G., Roskams T., Larusso N.F., et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003, 124:737-753.
33. Spirli C., Nathanson M.H., Fiorotto R., Duner E., Denson L.A., Sanz J.M., Di Virgilio F., et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001, 121:156-169.
34. Prieto J., Qian C., Garcia N., Diez J., Medina J.F. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 1993, 105:572-578.
35. Prieto J., Garcia N., Marti-Climent J.M., Penuelas I., Richter J.A., Medina J.F. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999, 117:167-172.
36. Arenas F., Hervias I., Uriz M., Joplin R., Prieto J., Medina J.F. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008, 118:695-709.
37. Paumgartner G., Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004, 8:67-81. vi.
38. Uriz M., Saez E., Prieto J., Medina J.F., Banales J.M. Ursodeoxycholic acid is conjugated with taurine to promote secretinstimulated biliary hydrocholeresis in the normal rat. PLoS One 2011, 6:e28717.
39. Ikebuchi Y, Shimizu H, Ito K, Yoshikado T, Yamanashi Y, Takada T, Suzuki H. Ursodeoxycholic acid stimulates the formation of the bile canalicular network. Biochem Pharmacol 2012;In press.
40. Guldutuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993, 104:1736-1744.
41. Rodrigues C.M., Fan G., Wong P.Y., Kren B.T., Steer C.J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998, 4:165-178.
42. Mitsuyoshi H., Nakashima T., Sumida Y., Yoh T., Nakajima Y., Ishikawa H., Inaba K., et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999, 263:537-542.
43. Ljubuncic P., Tanne Z., Bomzon A. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci 2000, 45:1921-1928.
44. Rodriguez-Ortigosa C.M., Cincu R.N., Sanz S., Ruiz F., Quiroga J., Prieto J. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 2002, 50:701-706.
45. Bernstein C., Payne C.M., Bernstein H., Garewal H. Activation of the metallothionein IIA promoter and other key stress response elements by ursodeoxycholate in HepG2 cells: relevance to the cytoprotective function of ursodeoxycholate. Pharmacology 2002, 65:2-9.
46. Lapenna D., Ciofani G., Festi D., Neri M., Pierdomenico S.D., Giamberardino M.A., Cuccurullo F. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002, 64:1661-1667.
47. Kawata K., Kobayashi Y., Souda K., Kawamura K., Sumiyoshi S., Takahashi Y., Noritake H., et al. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. Antioxid Redox Signal 2010, 13:259-268.
48. Yang H., Ramani K., Xia M., Ko K.S., Li T.W., Oh P., Li J., et al. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology 2009, 49:1982-1991.
49. Arisawa S., Ishida K., Kameyama N., Ueyama J., Hattori A., Tatsumi Y., Hayashi H., et al. Ursodeoxycholic acid induces glutathione synthesis through activation of PI3K/Akt pathway in HepG2 cells. Biochem Pharmacol 2009, 77:858-866.
50. Okada K., Shoda J., Taguchi K., Maher J.M., Ishizaki K., Inoue Y., Ohtsuki M., et al. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 2008, 295:G735-G747.
51. Koga H., Sakisaka S., Ohishi M., Sata M., Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997, 25:1077-1084.
52. Allina J., Hu B., Sullivan D.M., Fiel M.I., Thung S.N., Bronk S.F., Huebert R.C., et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006, 27:232-241.
53. Xie Q., Khaoustov V.I., Chung C.C., Sohn J., Krishnan B., Lewis D.E., Yoffe B. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 2002, 36:592-601.
54. Qiao L., Yacoub A., Studer E., Gupta S., Pei X.Y., Grant S., Hylemon P.B., et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 2002, 35:779-789.
55. Schoemaker M.H., Conde de la Rosa L., Buist-Homan M., Vrenken T.E., Havinga R., Poelstra K., Haisma H.J., et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 2004, 39:1563-1573.
56. Sola S., Castro R.E., Kren B.T., Steer C.J., Rodrigues C.M. Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes. Biochemistry 2004, 43:8429-8438.
57. Amaral J.D., Xavier J.M., Steer C.J., Rodrigues C.M. The role of p53 in apoptosis. Discov Med 2010, 9:145-152.
58. Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990, 11:12-15.
59. Tanaka H., Makino Y., Miura T., Hirano F., Okamoto K., Komura K., Sato Y., et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996, 156:1601-1608.
60. Takahashi T., Miura T., Nakamura J., Yamada S., Miura T., Yanagi M., Matsuda Y., et al. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology 2012, 55:846-855.
61. Kikuchi K., Hsu W., Hosoya N., Moritoki Y., Kajiyama Y., Kawai T., Takai A., et al. Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. Hepatol Res 2009, 39:448-454.
62. Yoshikawa M., Tsujii T., Matsumura K., Yamao J., Matsumura Y., Kubo R., Fukui H., et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992, 16:358-364.
63. Ishizaki K., Iwaki T., Kinoshita S., Koyama M., Fukunari A., Tanaka H., Tsurufuji M., et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 2008, 578:57-64.
64. Unitt J., Hornigold D. Plant lectins are novel Toll-like receptor agonists. Biochem Pharmacol 2011, 81:1324-1328.
65. Tu C.T., Han B., Yao Q.Y., Zhang Y.A., Liu H.C., Zhang S.C. Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of Toll-like receptor (TLR) 2, TLR4 and TLR9 expression. Int Immunopharmacol 2012, 12:151-157.
66. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
67. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., Wendum D., Firrincieli D., Coilly A., Fouassier L., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009, 136:1435-1443.
68. Sadeghi K., Wessner B., Laggner U., Ploder M., Tamandl D., Friedl J., Zugel U., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogenassociated molecular patterns. Eur J Immunol 2006, 36:361-370.
69. Mattner J., Savage P.B., Leung P., Oertelt S.S., Wang V., Trivedi O., Scanlon S.T., et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008, 3:304-315.
70. Nishigaki Y., Ohnishi H., Moriwaki H., Muto Y. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci 1996, 41:1487-1493.
71. Mimura Y., Sakisaka S., Harada M., Sata M., Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology 1995, 109:1969-1976.
72. Tuin A., Huizinga-Van der Vlag A., van Loenen-Weemaes A.M., Meijer D.K., Poelstra K. On the role and fate of LPS-dephosphorylating activity in the rat liver. Am J Physiol Gastrointest Liver Physiol 2006, 290:G377-G385.
73. Sasatomi K., Noguchi K., Sakisaka S., Sata M., Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998, 29:409-416.
74. Harada K., Nakanuma Y. Biliary innate immunity in the pathogenesis of biliary diseases. Inflamm Allergy Drug Targets 2010, 9:83-90.
75. Harada K., Shimoda S., Sato Y., Isse K., Ikeda H., Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009, 157:261-270.
76. Harada K., Nakanuma Y. Cholangiopathy with respect to biliary innate immunity. Int J Hepatol 2012, 2012:793569.
77. Ide T., Sata M., Nakano H., Suzuki H., Tanikawa K. Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis. Hepatogastroenterology 1997, 44:1569-1573.
78. Ballot E., Bandin O., Chazouilleres O., Johanet C., Poupon R. Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases. J Autoimmun 2004, 22:153-158.
79. Fiorotto R., Scirpo R., Trauner M., Fabris L., Hoque R., Spirli C., Strazzabosco M. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-kappaB-mediated inflammatory response in mice. Gastroenterology 2011, 141:1498-1508. 1508 e1491-5.
80. Hagmann W., Denzlinger C., Keppler D. Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ Shock 1984, 14:223-235.
81. Schwarzenberg S.J., Bundy M. Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats. Pediatr Res 1994, 35:214-217.
82. Hori Y., Ohyanagi H. Protective effect of the intravenous administration of ursodeoxycholic acid against endotoxemia in rats with obstructive jaundice. Surg Today 1997, 27:140-144.
83. Miura T., Ouchida R., Yoshikawa N., Okamoto K., Makino Y., Nakamura T., Morimoto C., et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaBdependent transcription by ursodeoxycholic acid. J Biol Chem 2001, 276:47371-47378.
84. Treede I., Braun A., Sparla R., Kuhnel M., Giese T., Turner J.R., Anes E., et al. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 2007, 282:27155-27164.
85. Van Nieuwkerk C.M., Elferink R.P., Groen A.K., Ottenhoff R., Tytgat G.N., Dingemans K.P., Van Den Bergh Weerman M.A., et al. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996, 111:165-171.
86. Tsuboi K., Tazuma S., Nishioka T., Chayama K. Partial characterization of cytoprotective mechanisms of lecithin against bile salt-induced bile duct damage. J Gastroenterol 2004, 39:955-960.
87. Stiehl A., Rudolph G., Sauer P., Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995, 23:283-289.
88. Kano M., Shoda J., Irimura T., Ueda T., Iwasaki R., Urasaki T., Kawauchi Y., et al. Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. Hepatology 1998, 28:302-313.
89. Rosmorduc O., Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007, 2:29.
90. Hofmann A.F., Zakko S.F., Lira M., Clerici C., Hagey L.R., Lambert K.K., Steinbach J.H., et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 2005, 42:1391-1398.
91. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., Zatloukal K., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
92. Denk G.U., Maitz S., Wimmer R., Rust C., Invernizzi P., Ferdinandusse S., Kulik W., et al. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology 2010, 52:1758-1768.
93. Schote A.B., Turner J.D., Schiltz J., Muller C.P. Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 2007, 44:1436-1445.
94. Campana G., Pasini P., Roda A., Spampinato S. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. Biochem Pharmacol 2005, 69:1755-1763.
95. Sinha J., Chen F., Miloh T., Burns R.C., Yu Z., Shneider B.L. beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. Am J Physiol Gastrointest Liver Physiol 2008, 295:G996-G1003.
96. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005, 2:217-225.
97. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., Galardi C., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000, 6:517-526.
98. Denson L.A., Sturm E., Echevarria W., Zimmerman T.L., Makishima M., Mangelsdorf D.J., Karpen S.J. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001, 121:140-147.
99. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J., Suchy F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001, 276:28857-28865.
100. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., MacKenzie K.I., et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003, 112:1678-1687.
101. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002, 277:2908-2915.
102. Gnerre C., Blattler S., Kaufmann M.R., Looser R., Meyer U.A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004, 14:635-645.
103. Barbier O., Torra I.P., Sirvent A., Claudel T., Blanquart C., Duran-Sandoval D., Kuipers F., et al. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003, 124:1926-1940.
104. Song C.S., Echchgadda I., Baek B.S., Ahn S.C., Oh T., Roy A.K., Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J Biol Chem 2001, 276:42549-42556.
105. Wagner M., Fickert P., Zollner G., Fuchsbichler A., Silbert D., Tsybrovskyy O., Zatloukal K., et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003, 125:825-838.
106. Modica S., Petruzzelli M., Bellafante E., Murzilli S., Salvatore L., Celli N., Di Tullio G., et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012, 142:355-365. e351-4.
107. Baghdasaryan A., Claudel T., Gumhold J., Silbert D., Adorini L., Roda A., Vecchiotti S., et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/-(Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output. Hepatology 2011, 54:1303-1312.
108. Eloranta J.J., Jung D., Kullak-Ublick G.A. The human Na+- taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol 2006, 20:65-79.
109. Inagaki T., Moschetta A., Lee Y.K., Peng L., Zhao G., Downes M., Yu R.T., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006, 103:3920-3925.
110. Wang Y.D., Chen W.D., Wang M., Yu D., Forman B.M., Huang W., Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008, 48:1632-1643.
111. Mencarelli A., Renga B., Migliorati M., Cipriani S., Distrutti E., Santucci L., Fiorucci S. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 2009, 183:6657-6666.
112. Chignard N., Mergey M., Barbu V., Finzi L., Tiret E., Paul A., Housset C. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology 2005, 42:549-557.
113. Lee F.Y., Kast-Woelbern H.R., Chang J., Luo G., Jones S.A., Fishbein M.C., Edwards P.A. Alpha-crystallin is a target gene of the farnesoid X-activated receptor in human livers. J Biol Chem 2005, 280:31792-31800.
114. Pellicciari R., Fiorucci S., Camaioni E., Clerici C., Costantino G., Maloney P.R., Morelli A., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002, 45:3569-3572.
115. Kowdley K.V., Luketic V.A., Jones D.E., Chapman R.W., Burroughs A.K., Hirschfield G.M., Poupon R., et al. The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC 2011, 416A-417A. Hepatology, San Francisco, CA.
116. Kowdley K.V., Jones D., Luketic V., Chapman R., Burroughs A., Hirschfield G., Poupon R., et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 2011, S13. 55.
117. Sharma R., Prichard D., Majer F., Byrne A.M., Kelleher D., Long A., Gilmer J.F. Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators. J Med Chem 2011, 54:122-130.